(NASDAQ: CADL) Candel Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.2%.
Candel Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CADL's revenue for 2027 to be $1,538,152,245, with the lowest CADL revenue forecast at $1,538,152,245, and the highest CADL revenue forecast at $1,538,152,245. On average, 1 Wall Street analysts forecast CADL's revenue for 2028 to be $4,383,984,413, with the lowest CADL revenue forecast at $4,383,984,413, and the highest CADL revenue forecast at $4,383,984,413.
In 2029, CADL is forecast to generate $14,374,458,605 in revenue, with the lowest revenue forecast at $14,374,458,605 and the highest revenue forecast at $14,374,458,605.